Healthcare entity

Michael Egholm

Person

Every one of those 1 sits in a single category, market-trends. Evolent is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6 in the same window.

Last mentioned: Feb 24, 2026

Entity pulse

Recent coverage · Michael Egholm

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Michael Egholm

Every one of those 1 sits in a single category, market-trends. Evolent is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6 in the same window. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. Michael Egholm appears in 1 tracked Healthcare story from February 24, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Michael Egholm. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Earnings Release

    Both EVH and LAB report full-year 2025 financial results to the market.

  2. Asset Realignment

    Standard BioTools completes a significant acquisition/disposition of assets per SEC filings.

  3. Operational Update

    Standard BioTools provides preliminary 2025 performance data and strategic outlook.

  4. SomaLogic Merger

    Standard BioTools completes merger with SomaLogic to expand proteomics capabilities.

Stories mentioning Michael Egholm 1

Market Trends Neutral

Evolent and Standard BioTools Q4 Results Signal Strategic Pivot to Profitability

Evolent and Standard BioTools reported Q4 and full-year 2025 financial results, highlighting a sector-wide shift toward operational efficiency and consolidation. While Evolent scales its specialty care management platform, Standard BioTools is navigating the final stages of its SomaLogic integration amidst a complex life sciences market.

2 sources

Source: prnewswire.com · manilatimes.net

Michael Egholm is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.